Carcinoid Tumors

Clinical Manifestations

The clinical manifestations of carcinoid tumors vary greatly depending on several factors, including tumor location, size, presence of metastasis, and ability to secrete bioactive substances. Many types of cancer are asymptomatic and are accidentally discovered during imaging studies or surgical procedures for unrelated diseases. However, when symptoms do appear, they can be divided into two categories: local symptoms caused by the tumor's lump effect or invasion of surrounding tissues, and systemic symptoms caused by the secretion of hormones and other bioactive molecules (carcinoid syndrome).

Local Symptoms

Local symptoms vary depending on the anatomical location of the tumor. For example, gastric cancer may cause symptoms such as abdominal pain, nausea, vomiting, and upper gastrointestinal bleeding (due to tumor ulcers). Lung cancer can manifest as coughing, hemoptysis (coughing up blood), chest pain, shortness of breath, or recurrent pneumonia, especially when the tumor blocks the bronchi. Rectal carcinoid tumors may cause rectal bleeding, constipation, diarrhea, or a feeling of incomplete emptying, while ileal carcinoid tumors may cause intestinal obstruction, abdominal spasms, and malabsorption (due to inflammation or obstruction caused by tumors leading to impaired nutrient absorption).

Figure 2. Local Symptoms.

Carcinoid Syndrome

Carcinoid syndrome is a rare but unique systemic symptom that occurs in approximately 10-20% of cancer patients, with the most common being metastatic colorectal cancer (especially liver) patients. This syndrome occurs when bioactive substances secreted by tumors, such as serotonin, histamine, kallikrein, and prostaglandins, bypass the liver's detoxification mechanism and enter the systemic circulation. The most common symptoms of carcinoid syndrome include:

Figure 3. Carcinoid Syndrome.

Redness: Intermittent redness and fever in the face, neck, and upper chest, usually caused by stress, alcohol, spicy food, or certain medications. The onset of flushing usually lasts for several minutes to several hours, and may be accompanied by sweating, palpitations, or feelings of anxiety.

Diarrhea: watery, frequent diarrhea (usually 10-20 bowel movements per day), often more severe after meals. Chronic diarrhea can lead to dehydration, electrolyte imbalance, and weight loss.

Bronchial spasm: wheezing, shortness of breath, and chest tightness, which may be misdiagnosed as asthma. Bronchial spasm is caused by the release of histamine and other bronchoconstrictors from tumors.

Cardiac manifestations: Carcinoid heart disease (CHD) is a serious complication of the long-standing carcinoid syndrome, which occurs in approximately 50% of symptomatic patients. Its characteristic is fibrosis (scar formation) of the heart valves, especially the tricuspid and pulmonary valves, leading to valve regurgitation (blood reflux) and ultimately resulting in heart failure. The symptoms of coronary heart disease include fatigue, edema (swelling in the legs and ankles), and shortness of breath due to exertion.

Laboratory testing

Laboratory testing plays a crucial role in the diagnosis and monitoring of carcinoid tumors. The most commonly used biochemical markers are:

Chromogranin A (CgA): a glycoprotein secreted by neuroendocrine cells, CgA is elevated in approximately 70-90% of cancer patients. It is a sensitive biomarker, but not highly specific, as elevated levels can also be seen in other neuroendocrine tumors, chronic renal failure, and certain inflammatory conditions. CgA levels are commonly used to monitor disease progression and response to treatment.

Urine 5-hydroxyindoleacetic acid (5-HIAA): 5-HIAA is the main metabolite of serotonin, and elevated levels in 24-hour urine collection have high specificity for carcinoid syndrome, especially in the midgut. However, 5-HIAA levels may be influenced by diet (such as serotonin rich foods like bananas, pineapples, and walnuts) and certain medications (such as acetaminophen, aspirin), so it is recommended that patients avoid using these substances 48-72 hours before testing.

Other hormone markers: Based on the location of the tumor and hormone secretion, other markers can be measured, such as gastrin (for gastric cancer), somatostatin (for growth inhibiting tumors), or pancreatic peptides (for pancreatic cancer).

Prognosis

The prognosis of carcinoid tumors varies due to multiple factors, including tumor location, size, staging, grading, and the presence of metastasis. Overall, the prognosis of carcinoid tumors is better than most other types of cancer, with a 5-year survival rate of approximately 67% for all patients. However, there are significant differences in prognosis among different subtypes:

Prognosis	Details
Localized tumors:	Patients with small localized carcinoid tumors (such as appendiceal or rectal carcinoid tumors smaller than 1 centimeter) have a good prognosis, with a 5-year survival rate of nearly 100% after surgical resection.
Metastatic tumors:	Patients with metastatic carcinoid tumors (especially liver metastases) have a poor prognosis, with a 5-year survival rate of approximately 30-40%. However, with advances in medical and local treatments, many patients with metastatic diseases can survive for 10 years or longer with well controlled symptoms.
Tumor grading:	The prognosis of atypical carcinoid (with a higher mitotic rate and possible necrosis) is worse than that of typical carcinoid, with a higher risk of recurrence and metastasis. The 5-year survival rate for atypical lung cancer is approximately 60-70%, while for typical lung cancer it is 90%.
Cancer like syndrome and heart disease	The presence of cancer like syndrome, especially cancer like heart disease, is associated with poor prognosis. The median survival of untreated patients with cancer like heart disease is 2-3 years, but early diagnosis and treatment (including valve replacement surgery) can significantly improve prognosis.

Conclusions

Carcinoid tumors are a group of neuroendocrine tumors with different clinical behaviors and outcomes. Although they are relatively rare, the incidence rate is rising. Early diagnosis and appropriate treatment are crucial to improve the survival rate and quality of life of patients. The progress of molecular biology and targeted therapy is expected to further improve the management of these challenging tumors in the future.

Inquiry Basket

Loading ......

Inquiry

Cat. No.	Product Name	Host	Isotype	Application
CABT-L3025	Mouse Anti-Human Neurofilament monoclonal antibody, clone JID750	Mouse	IgG	IHC	Inquiry
CABT-L3025	Mouse Anti-Human Neurofilament monoclonal antibody, clone JID750	Mouse	IgG	IHC	Inquiry
DMAB-L21045	Mouse Anti-Human NSE monoclonal antibody, clone 712	Mouse	IgG1	ELISA(Cap), ELISA(Det)	Inquiry

Cat. No.	Product Name	Size	Species Reactivity	Application	Detection Method
DEIA-JY2408	Serotonin ELISA kit	96T	Human	Quantitative	ELISA	Inquiry